Major depressive disorder (MDD) is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite[3]. (1S-cis)-Milnacipran Hydrochloride is the latest antidepressants approved for the treatment of MDD. It acts through an increased serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT). In addition to the SSRI activity, (1S-cis)-Milnacipran Hydrochloride is also a norepinephrine reuptake inhibitor[4]. In seven randomised, double-blind clinical trials, levomilnacipran is generally more effective than placebo for the treatment of MDD in the short-term. Preliminary evidence suggests that levomilnacipran extended release may be effective in improving not only depressive symptoms but also symptoms related to functioning (social life, work, and family life)[5].
搜索
